We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Traws Pharma Inc (TRAW) USD0.01

Sell:$0.62 Buy:$0.66 Change: $0.0118 (1.87%)
Market closed |  Prices as at close on 24 May 2024 | Switch to live prices |
Sell:$0.62
Buy:$0.66
Change: $0.0118 (1.87%)
Market closed |  Prices as at close on 24 May 2024 | Switch to live prices |
Sell:$0.62
Buy:$0.66
Change: $0.0118 (1.87%)
Market closed |  Prices as at close on 24 May 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Traws Pharma, Inc., formerly Onconova Therapeutics, Inc., is a virology and oncology company. The Company is engaged in developing antivirals for influenza, COVID and other respiratory infections and narazaciclib. Its proprietary portfolio includes, TRX100 (viroksavir), TRX01 (travaltrevir), and Narazaciclib. Viroksavir is a cap-dependent endonuclease inhibitor for influenza. Travaltrevir is a Mpro protease inhibitor for COVID19. Narazaciclib is a cyclin-dependent kinases (CDK) 4/6 inhibitor for low-grade endometrioid endometrial cancer (LGEEC). Narazaciclib’s mechanism of action in LGEEC is validated by phase II studies with other approved CDK4/6 inhibitors: palbociclib, ribociclib, and abemaciclib. Narazaciclib is in phase I/IIa study to define the Phase II dose (RP2D).

Contact details

Address:
12 Penns Trail
NEWTOWN
18940
United States
Telephone:
+1 (267) 7593680
Website:
https://www.onconova.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
TRAW
ISIN:
US68232V8019
Market cap:
$15.70 million
Shares in issue:
25.30 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Iain Dukes
    Executive Chairman of the Board
  • Steven Fruchtman
    President
  • Werner Cautreels
    Chief Executive Officer, Director
  • Nikolay Savchuk
    Chief Operating Officer, Director
  • C. David Pauza
    Chief Scientific Officer, Virology
  • Robert Redfield
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.